Startups Directory

Deep-Tech in symbiotic micro-biotechnology that develops ultra-high-density biological solutions (SymBio-HD™) and intelligent microbial consortia (SEC™) to solve global crises in agriculture, pharmaceuticals, and the environment through a dual B2B and B2G (licensing) model. Our technology achieves densities 100 times higher, carbon footprints 81% lower, stability for 120 days, and costs 66% lower than our competitors.

Unfeasible costs of Pesticides and fertilizers; European targets (Farm-to-Fork and CAP) to reduce agrochemicals by 50%

Our technology increases agricultural productivity by 30%, reduces the carbon footprint by 81%, reduces water consumption by 40% and agrochemicals by 30%; and all this at a cost 66% lower than the market average, generating a return for the farmer of between 45 and 65%. It is a concept that integrates the solution to eradicating hunger (thanks to increased crop yields) and solving climate change (by reducing the carbon footprint by 81%).

€600k

€1,2M

A MedTech that has developed a medical device to make the endotracheal intubation procedure, even in critical settings, easier, faster and safer, helping to save lives.

Endotracheal Intubation (ETI) is the 3rd most performed medical procedure in all hospitals worldwide, with more than 100 million intubations per year. It is a procedure that requires highly skilled specialists. It is performed not only in operating theatres by anaesthesiologists, but also in critically ill patients by intensive care and emergency specialists, and in pre-hospital settings by less trained professionals. The ETI is a critical medical procedure that provides artificial ventilation, making anaesthesia possible for surgery and ensuring emergency care for critically ill patients, where airway control is the first step in resuscitation.The global airway market is estimated to be worth a total of USD 2.61 billion by the end of 2025. However, ETI is a high-risk procedure for patients and healthcare workers, with a high complication rate. In fact, 45% of intubations in critically ill patients result in serious complications. The procedure is complex due to the difficulty of obtaining a clear view and guiding the ETT from the patient’s mouth into the trachea. Stylets and bougies are the most commonly used tools to aid endotracheal tube placement, improving first-attempt success but causing trauma to the patient. A wide range of devices (channelled videolaryngoscopes, fibreoptic bronchoscopes, and oropharyngeal cannulas) have been developed to facilitate intubation. Despite these efforts and technological advancements, practical difficulties persist, highlighting that a truly reliable and universally effective solution has yet to be found.

ETI failure rates can reach up to 45% in emergency cases and prehospital environments, when time is more crucial and trained personnel are less available, making it the leading cause of preventable trauma‐related deaths worldwide. On the battlefield, airway compromise is the second leading cause of potentially survivable death, responsible for 1 in 10 preventable fatalities in the case of the US Military

800.000 euros

800.000 euros

We use green biotechnology (enzymatic hydrolysis) to develop, ad hoc, bioactive ingredients from natural raw materials, including agrifood by-products. These ingredients are science-backed and ready to incroporate in final products for functional food, nutraceuticals and healthcare, cosmetics and pet and veterinary products.

There is a lack of agrifood by-products revalorization, causing a major environmental problem. Moreover, more and more customers expect additonal functionalities in their daily products (food, cosmetics and pets), increasing the pressure for innovation in these sectors, and the necessity for including innovative functional ingredients in their products.

We will help to reduce the agrifood waste, contributing to circular economy. Moreover, we will increase the overall health and wellness of customers and their pets.

200.000-300.000€

300.000€

Research and development of novel AI-based tools for precision medicine

Patient-tailored configuration of medical exams

More scalable, accurate, and reproducibile medical exams

€600.000

€1.200.000

ENDOMET develops MVP11, a small molecule that restores mitochondrial energy by switching on endogenous CoQ biosynthesis, targeting rare metabolic disorders and female reproductive health.

Due to its vital importance, there are more than 370 clinical trials in which Coenzyme Q10 has been used as a therapeutic agent. However, these trials have failed due to: 1) the low bioavailability and tissue absorption of CoQ10; 2) the very limited access to the mitochondrion, which is the cell’s power plant.; and 3) the fact that they do not increase the levels of other forms of CoQ, also required for energy production.

Our technology will have a threefold impact on society: 1) Clinical benefits: better outcomes in severe mitochondrial and metabolic diseases and in female reproductive health. 2) Improved quality of life: more functional independence for patients and relief for families and caregivers. 3) Reduced healthcare costs: fewer hospitalizations, fewer complex procedures, and more efficient use of healthcare resources.

100 - 900 k

We are raising a €2.5 million seed round in total.

Aurax is a Barcelona-based HealthTech startup developing breakthrough hands-free human–machine interfaces. Our first product, MouthX, is a patented intraoral controller that uses subtle tongue, jaw and head movements to deliver full digital autonomy for people with limited upper-limb mobility. Combining advanced sensing technology, custom-fit design and seamless multi-device integration, Aurax aims to redefine accessible interaction and become a global reference in inclusive innovation.

MouthX addresses the lack of effective, precise and dignified hands-free control solutions for people with limited upper-limb mobility. Current assistive technologies are slow, uncomfortable, environmentally dependent or offer only partial functionality. As a result, millions of users cannot operate smartphones, computers or digital services independently. MouthX solves this by enabling full multidimensional digital control through subtle tongue, jaw and head movements, providing a fast, reliable and intuitive alternative that restores digital autonomy and reduces dependence on caregivers. It also overcomes key limitations of existing systems such as poor precision, fatigue, bulky hardware and limited portability.

MouthX has the potential to significantly improve digital inclusion by giving millions of people with limited upper-limb mobility full independent access to smartphones, computers and digital services. By restoring digital autonomy, the technology reduces reliance on caregivers and enables individuals to participate more fully in education, employment and social interaction. Beyond accessibility, MouthX introduces a new hands-free interaction paradigm that can be applied across healthcare, industry and high-demand professional environments. Its impact extends from empowering individuals to reducing social inequalities and accelerating the adoption of inclusive technologies that benefit society as a whole.

We are preparing a €5M Series A round for the second half of 2026, led by an industrial partner. This funding will support clinical trials and the regulatory pathway for the Medical Device version of MouthX, expand our product line, strengthen key strategic hires and accelerate international go-to-market efforts.

€5 million.

Flavii Therapeutics is a spin-off from the University of Barcelona developing first-in-class epigenetic therapies for central nervous system disorders. Our mission is to advance novel, mechanism-driven compounds from preclinical development into clinical trials. Our lead candidate, FLAV-27, is a highly potent and selective G9a inhibitor with excellent pharmacokinetics and strong brain penetration, clearly outperforming previous compounds in its class. To date, FLAV-27 has shown no toxicity, demonstrates a wide therapeutic window, and has robust efficacy across validated animal models of Alzheimer’s disease, Huntington’s disease, and additional neurodevelopmental disorders. Flavii Therapeutics is now preparing to accelerate its translational pathway and represents a compelling investment opportunity for partners interested in transformative CNS therapies.

Only 10% of drug development is focused on treating neurological diseases, including neurodegenerative conditions like Huntington's and Alzheimer's, as well as neurodevelopmental disorders. These diseases have very different etiologies but share one common factor: there is still no cure. In recent years, symptomatic treatments have been developed, but none have addressed disease progression or reversed it. At Flavii, our mission is to provide solutions for this unmet medical need. Flavii has developed FLAV-27, a first-in-class epigenetic therapy to treat central nervous system disorders. It belongs to a novel generation of selective G9a inhibitors that combine high in vitro potency with an improved safety profile. Unlike earlier G9a inhibitors such as UNC0642, which demonstrated neuroprotective potential but failed due to poor ADMET properties and insufficient blood–brain barrier (BBB) penetration, FLAV-27 exhibits favorable pharmacokinetics, achieving a 3.8-fold higher brain-to-plasma ratio. Preclinical studies in mouse models of both neurodegenerative and neurodevelopmental diseases confirm its neuroprotective effects, while toxicology data support its safety and tolerability. By overcoming key translational barriers in CNS drug development, FLAV-27 offers a highly innovative therapeutic strategy that goes beyond symptomatic treatment to directly target disease-modifying mechanisms.

Neurodegenerative diseases such as Alzheimer’s and Huntington’s impose an enormous personal, social, and economic burden. Patients suffer progressive cognitive, motor, and psychiatric decline, severely impacting their independence and quality of life. Caregivers and families face high emotional stress, often dedicating years of intensive care, with significant physical, psychological, and financial consequences. The development of a disease-modifying therapy that can slow, halt, or even prevent disease progression would be transformative. For patients, it could preserve cognitive and motor functions, maintain independence, and significantly improve quality of life. For caregivers and families, it would reduce emotional and physical strain, allowing them to maintain a healthier lifestyle and social relationships. Broadly, such treatments would decrease the long-term healthcare and social costs associated with these devastating diseases, providing substantial societal benefits while addressing a critical unmet medical need.

200K€

The pre-seed investment round amounts to €500K€

FORMACHÉ S.L., a technology company in the Tenerife ZEC zone, is a spin-off of the University of La Laguna (ULL) created following a research program (2019-2023) led by Carlos Morán and Damián de Torres. It began operations in 2024, leveraging ULL patents to offer scientific research services and create sustainable materials from the transformation of agricultural waste.

We formulate new materials for technological applications using agricultural waste, promoting innovation in recycling and the circular economy. These applications currently focus on materials for additive manufacturing using liquid material deposition.

Creating materials that incorporate waste reduces landfill occupancy, reduces the use of petroleum-based plastics, and provides mechanisms for the better use of raw materials. We promote the creation of processes that improve the implementation of the circular economy, so that, through knowledge transfer, they generate value propositions that can be transformed into new business models.

N/A

N/A

EoxSense is a health-tech startup developing biosensors to track real-time biomarkers with high precision. These sensors can monitor multiple biomarkers in sweat, non-invasively, wearing a small, patch-like device on the skin: no needles, no blood draw, and no battery required. The proprietary solid-state sensor continuously measures glucose, lactate, and more as you exercise, then streams raw signals wirelessly to the secure cloud platform. In lab-stage tests, the readings correlated closely with gold-standard blood measurements - a breakthrough others have struggled to achieve. Unique noise-filtering design ensures stable, reliable data. The AI instantly turns data into actionable insights. Through the smartphone app, get real-time alerts on lactic thresholds, glucose dips, hydration, and refuel recommendations - so a beat is never missed. Real-time, clinically relevant insights in a simple, self-powered wearable.

Economical and efficient biochemical sensing: using solid-state electrochemical detection technologies, EOXSense reduces the complexity of sensors, making them more compact and affordable without losing precision or reliability. Access to health parameter information outside the laboratory: to respond to the demand generated during the pandemic (and beyond), it allows the measurement of indicators such as glucose, lactate or cancer markers continuously and practically, in uncontrolled environments. Real-time monitoring via wearables: its platforms are designed for use in IoT and wearable technology, monitor sweat and other body fluids, sending data to the cloud with artificial intelligence for the personalization of biomedical consultations. Improved diagnosis and treatment of chronic diseases: the use of these sensors contributes to earlier diagnosis (diabetes, cardiovascular, neurological pathologies, etc.) and allows more specific and tailored treatments for each patient.

EOXSense’s technology will have a transformative impact on society by enabling affordable, real-time health monitoring outside traditional laboratories. It supports early diagnosis and personalized treatment of chronic diseases, reduces healthcare costs, and promotes preventive health habits. By integrating with IoT and AI, it empowers telemedicine and data-driven public health strategies, improving accessibility and equity in healthcare. Beyond medicine, it enhances sports performance and well-being, fostering a culture of proactive health management.

VORS develops advanced control solutions for industrial systems and processes

Industrial systems and processes often suffer from: -Instabilities that reduce productivity, quality and reliability -Mechanical vibrations that accelerate component wear and reduce their lifetime -Reference tracking error that modifies the system set-point -External disturbances that degrade performance -Uncertain or variable system dynamics leading to unpredictable behavior

By solving industrial systems and processes control problems our technology extends the lifetime of industrial equipment, reduces energy waste, and improves production reliability. This leads to lower resource consumption, fewer unplanned shutdowns, and more sustainable industrial operations—benefiting both the economy and the environment.

N/A

N/A

Our startup is a deep-tech spin-off developing advanced electrochemical systems based on proprietary 3D graphene materials for the on-site destruction of PFAS and other persistent contaminants. Building on more than a decade of cutting-edge research, we provide modular, energy-efficient treatment units that eliminate harmful pollutants without generating toxic byproducts. Our mission is to deliver scalable, reliable, and sustainable solutions that help industries and communities meet strict environmental standards while reducing long-term liabilities.

Our technology addresses one of the most urgent environmental challenges: the effective elimination of PFAS and other highly persistent organic contaminants from water. Traditional treatment methods can only separate or concentrate these pollutants, often transferring the problem elsewhere and creating long-term environmental and financial liabilities. In contrast, our electrochemical system completely destroys PFAS on-site, preventing their accumulation in the environment and avoiding costly off-site disposal. It also solves key operational challenges faced by industries and utilities, such as the need to treat complex water matrices, reduce hazardous waste, comply with increasingly strict regulations, and ensure safe, reliable, and energy-efficient treatment. By providing a scalable and modular solution that does not generate toxic byproducts, our technology enables true contaminant destruction where conventional technologies fall short.

PFAS are linked to serious health problems, including cancer, reduced immune response, hormonal disruption, fertility issues, and developmental effects in children. Because these chemicals accumulate in the human body and the environment, even low-level exposure through drinking water, food, or everyday products can pose long-term risks to public health. Our technology directly addresses this problem by destroying PFAS on-site, preventing them from entering water supplies, accumulating in ecosystems, or cycling back into the food chain. By eliminating PFAS instead of merely concentrating or transferring them, our solution reduces human exposure at the source and helps protect communities from the chronic health impacts associated with these “forever chemicals.” In doing so, our technology contributes to healthier populations, lowers future healthcare burdens, and supports safer and more sustainable water management practices.

€1.5M

€1.5M

Development of new enzymatic active ingredients (enzybiotics) with antibacterial activity against priority pathogens in the food industry

Food Poisoning Antimicrobial Resistance

This technology is expected to offer a multiple impact on society through different means: 1) to increase food-safety conditions with specific anti-bacterial products; 2) to mitigate the spread of antimicrobial resistance; 3) to contribute to a safer work environment through the use of non-toxic biocides; 4) to mitigate the environmental impact of the use of disinfectant formulations.

€200.000

€200.000

Our mission is to revolutionize healthcare by ensuring accessible, high-quality testing for everyone, regardless of location or economic status.

Extremly expensive, heavy infrastructures, low and middle income regions, rural and remote areas, democratize access and improve healthcare, high income countries

To provide acces to MRI testing in emerging countries where MRI tests are rarely performed, as these machines are hardly available.

3.000.000€

3.000.000€

Tesoro Imaging S.L. is a spin-off of Institute of Molecular Imaging Instrumentation (i3M) of the CSIC and the UPV, which is developing a mobile and low cost magnetic resonance system that means a disruption in the brain and dental medical imaging market.

Extremly expensive, high income countries, rural and remote areas, democratize access and improve healthcare

To revolutionize healthcare by ensuring accessible, high-quality testing for everyone, regardless of location or economic status

1.5M€

1.5M€

We reduce the energy lost due to undetected or poorly prioritized anomalies and eliminate the lack of traceability and comparability between inspections throughout the lifespan of photovoltaic installations.

Reducimos la energía que se pierde por anomalías no detectadas o mal priorizadas y eliminamos la falta de trazabilidad y comparabilidad entre inspecciones a lo largo de la vida útil de la instalación.

It addresses a critical environmental problem: energy inefficiency and structural losses in solar installations, which reduce their actual contribution to the energy transition. Undetected thermal anomalies generate production losses, overheating, and a risk of fire on industrial roofs, with both economic and environmental impacts. Our technology allows for the early detection, classification, and prioritization of anomalies, optimizing the performance of renewable assets and reducing their operational footprint. This translates into more clean energy generated with the same infrastructure, greater safety, and a reduced need for module replacement. In doing so, we directly contribute to the decarbonization and efficiency goals of the photovoltaic sector.

€100.000

€200.000